Oncology & Cancer

Reasons for TKI discontinuation ID'd in chronic myeloid leukemia

(HealthDay)—For patients with chronic myeloid leukemia (CML), tyrosine kinase inhibitor (TKI) therapy can be safely discontinued and yields high rates of treatment-free remission (TFR), according to a study published online ...

Oncology & Cancer

Ibrance approval expanded to include men with breast cancer

(HealthDay)—U.S. Food and Drug Administration approval of Ibrance (palbociclib) capsules has been widened to include men with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced or metastatic ...

Oncology & Cancer

Tarloxotinib promising against NRG1-fusion cancers

A study by University of Colorado Cancer Center and Rain Therapeutics, Inc. presented at the American Association for Cancer Research (AACR) Annual Meeting 2019 shows that the clinical-stage drug, tarloxotinib, is active ...

Oncology & Cancer

Tobacco use makes precancerous cells that fertilize cancer growth

Tobacco use causes a field of precancerous cells, increasing the risk of developing head & neck cancer. But exactly how this precancerous field influences cancer has been often overlooked. Now a University of Colorado Cancer ...

Medications

Origin of resistance to lung-cancer drug discovered

Researchers at Kanazawa University report in Nature Communications that AXL, a protein belonging to the class of receptor tyrosine kinases, causes some lung cancer patients to have an intrinsic resistance to the drug osimertinib. ...

Oncology & Cancer

Melanoma: dabrafenib and trametinib have added benefit

The German Institute for Quality and Efficiency in Health Care (IQWiG) investigated whether the drug combinations of dabrafenib plus trametinib and of encorafenib plus binimetinib have an added benefit in comparison with ...

Oncology & Cancer

New drug combination could be more effective against melanoma

A class of cancer drugs called protein kinase inhibitors is one of the most effective treatments for melanoma. However, in many cases, tumors eventually become resistant to the drugs and cause a relapse in the patient.

page 2 from 19